We are live on ! Find out more
GTBP icon

GT Biopharma
GTBP

33 hedge funds and large institutions have $895K invested in GT Biopharma in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 6

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

5% more capital invested

Capital invested by funds: $850K → $895K (+$45.2K)

3% more funds holding

Funds holding: 32 → 33 (+1)

0.01% less ownership

Funds ownership: 0.28% → 0.28% (-0.01%)

Holders
33
Holders Change
+1
Holders Change %
+3.13%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
9
Reduced
6
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$14.1K
2
Renaissance Technologies
Renaissance Technologies
New York
+$11.7K
3
LPL Financial
LPL Financial
California
+$8.36K
4
HF
HRT Financial
New York
+$8.23K
5
MG
Marex Group
+$7.31K

Top Sellers

Rank Fund Capital Flow
1
BFS
Baskin Financial Services
Ontario, Canada
-$36K
2
CLOS
Compagnie Lombard Odier SCmA
Switzerland
-$12.1K
3
Millennium Management
Millennium Management
New York
-$5.38K
4
SPC
Sigma Planning Corp
Michigan
-$4.92K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$3.36K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$277K +$183 +25 +0.1%
Bank of Montreal
2
Bank of Montreal
Ontario, Canada
$170K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$86K – – –
BlackRock
4
BlackRock
New York
$77.5K – – –
Wells Fargo
5
Wells Fargo
California
$76.7K +$7 +1 +0%
Renaissance Technologies
6
Renaissance Technologies
New York
$29K +$11.7K +1,600 +72%
AWS
7
Atria Wealth Solutions
New York
$25.2K +$2.44K +334 +11%
Bank of New York Mellon
8
Bank of New York Mellon
New York
$24.3K – – –
State Street
9
State Street
Massachusetts
$20.4K – – –
Millennium Management
10
Millennium Management
New York
$16.8K -$5.38K -736 -25%
Citadel Advisors
11
Citadel Advisors
Florida
$14.7K +$14.1K +1,927 New
TSS
12
Two Sigma Securities
New York
$9.48K +$1.51K +207 +20%
LPL Financial
13
LPL Financial
California
$8.75K +$8.36K +1,144 New
Northern Trust
14
Northern Trust
Illinois
$8.25K – – –
HF
15
HRT Financial
New York
$8K +$8.23K +1,126 New
MG
16
Marex Group
$7.65K +$7.31K +1,000 New
Goldman Sachs
17
Goldman Sachs
New York
$5.83K +$3.03K +415 +120%
MAWA
18
Moss Adams Wealth Advisors
Washington
$5.1K – – –
TRCT
19
Tower Research Capital (TRC)
New York
$5.04K -$95 -13 -2%
Jane Street
20
Jane Street
New York
$4.95K +$4.73K +647 New
Morgan Stanley
21
Morgan Stanley
New York
$4.12K +$1.97K +270 +100%
UBS Group
22
UBS Group
Switzerland
$3.72K +$1.43K +195 +67%
Commonwealth Equity Services
23
Commonwealth Equity Services
Massachusetts
$3K – – –
WG
24
Welch Group
Alabama
$2.55K – – –
Bank of America
25
Bank of America
North Carolina
$273 +$139 +19 +112%
1
2

GTBP Hedge Fund Activity: Q4 2023 in Review

33 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q4 2023, worth a combined $895K — up 5.3% from $850K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new GTBP positions and 5 closed out — a net gain of 1 holder — while 9 added to existing stakes and 6 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $14.1K. The largest seller was Baskin Financial Services, exiting entirely with an estimated $36K sold.

  • 33 institutional investors held GT Biopharma (GTBP) as of Q4 2023, up from 32 in Q3 2023.
  • Funds reported $895K of GT Biopharma stock for Q4 2023, up 5.3% quarter-over-quarter.
  • 6 funds opened new GT Biopharma positions in Q4 2023 and 5 closed out, a net change of +1 holder.
  • The largest GT Biopharma buyer in Q4 2023 was Citadel Advisors, an estimated $14.1K added.
  • The largest GT Biopharma seller in Q4 2023 was Baskin Financial Services, an estimated $36K sold.

Based on aggregated 13F filings for Q4 2023.